Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)
Funding Opportunity RFA-HL-21-014 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enha...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 6, 2021 Category: Research Source Type: funding
Open Mike Perspective: Healthy Skepticism when Focusing Solely on Surrogate Endpoints in Clinical Research
I recently wrote an essay for the NIH’s Science, Health, and Public Trust series to encourage a healthy bit of skepticism about clinical studies that solely involve surrogate end-points (e.g. changes in “biomarkers” like blood cholesterol levels or findings on an electrocardiogram).
To make my point, I described experiences with a well-known cardiovascular trial — one that focused on the risk of sudden death among heart attack survivors. I encourage readers in this essay to not just assume that treating a surrogate endpoint will automatically treat the underlying condition. Sometimes it does. But sometimes it...
Source: NIH Extramural Nexus - May 3, 2018 Category: Research Authors: Mike Lauer Tags: blog Open Mike Clinical Trials innovation Perspectives Source Type: funding
